<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301806</url>
  </required_header>
  <id_info>
    <org_study_id>C-282-02</org_study_id>
    <nct_id>NCT02301806</nct_id>
  </id_info>
  <brief_title>Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM</brief_title>
  <official_title>A Randomized, Prospective, Parallel Design Study to Compare the Effectiveness of Sitagliptin Versus Glimepiride on Endothelial Dysfunction During an Oral Glucose Loading in Drug Naive Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dokkyo Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dokkyo Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether single administration of sitaglitpin can restore acute endothelial
      dysfunction and ameliorate impaired increase of the number of endothelial progenitor cells
      (EPCs) after oral glucose loading in patients with T2DM.

      To compare the effect of sitagliptin and glimepiride on endothelial function evaluated by
      flow-mediated vasodilatation (FMD) and the number of circulating EPCs in patients with T2DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute and chronic improvement of endothelial function is expected through the pleiotropic
      effect of DPP-4 inhibitors. A randomized, prospective, open-labeled, parallel design. The
      duration of treatments with sitagliptin or glimepiride is 12 weeks. The number of study
      centers is a single (Dokkyo Medical University Hospital). Participants will be randomized
      into the two treatment groups; (a) 50mg sitagliptin (N=15) and (b) 1mg glimepiride (N=15).

      Anti-Hyperglycemic effect is expected to be similar according to our study
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in endothelial function during the OGTT evaluated by flow-mediated vasodilatation (FMD). The change is defined as below, assuming the peak value and changes of FMD will be observed at t=60 min.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function during OGTT* evaluated by endo-PAT. Change in endothelial function after 12-week treatment at the fasting state evaluated by endo-PAT and FMD.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the number of EPCs after 12-week treatment</measure>
    <time_frame>12 weeeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sitagliptin 50 mg tablet by mouth 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glimepiride 1 mg tablet by mouth 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dieting</intervention_name>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>sitagliptin 50 mg tablet by mouth 12 weeks</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>glimepiride 1 mg tablet by mouth 12 weeks</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent before any study specific procedures

          -  Type II diabetes who have inadequate glycaemic control (6.5%≦HbA1c＜9.0%)

          -  Age from 20 to 80 years old

          -  No history of using any antihyperglycemic drugs

          -  No history of cardiovascular complications

          -  No treatment or treatment with stable doses of lipid-lowering, antihypertensive, and
             antiplatelet agents for at least 3 months prior to randomization

          -  4.5 % ≤ fasting FMD at baseline &lt; 8.0 %

        Exclusion Criteria:

          -  ・Type I diabetes

               -  Pregnancy

               -  Liver disease (hepatic enzymes more than three times the upper limit of normal
                  ranges)

               -  Impairared kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2
                  mg/dl in women)

               -  Cigarette smokers

               -  Contraindications to glimepiride and sitagliptin

               -  Active proliferative diabetic retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshimasa Aso</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokkyo Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoshimasa Aso, MD</last_name>
    <phone>81-282-86-1111</phone>
    <email>yaso@dokkyomed.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kunihiro Suzuki, MD</last_name>
    <phone>81-282-86-1111</phone>
    <email>kuni-s@dokkyomed.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dokkyo Medical University</name>
      <address>
        <city>Mibu</city>
        <state>Tochigo</state>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshimasa Aso, MD</last_name>
      <phone>81-282-86-1111</phone>
      <email>yaso@dokkyomed.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshimasa Aso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Mibu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dokkyo Medical University</investigator_affiliation>
    <investigator_full_name>Yoshimasa Aso</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

